PMID- 31390629
OWN - NLM
STAT- MEDLINE
DCOM- 20191007
LR  - 20191007
IS  - 1423-0232 (Electronic)
IS  - 0030-2414 (Linking)
VI  - 97
IP  - 4
DP  - 2019
TI  - Lenvatinib Long-Term Responses in Refractory Thyroid Cancer: Our 
      Mono-Institutional Real-Life Experience with the Multidisciplinary Approach and 
      Review of Literature.
PG  - 206-210
LID - 10.1159/000501691 [doi]
AB  - Lenvatinib (LEN) is a multikinase inhibitor with antiangiogenic properties 
      recently approved in radioactive iodine-refractory differentiated thyroid cancer, 
      hepatocellular carcinoma, and renal cell carcinoma in combination with 
      everolimus. LEN-treated patients frequently have adverse events (AEs) that 
      generally require such dose modifications, including drug discontinuation. 
      Hypertension, diarrhea, weight loss, proteinuria, fatigue, and palmar-plantar 
      erythrodysesthesia are reported among the most frequent AEs, often leading to 
      discontinuations or dose modifications. This paper reports a case series focusing 
      on the role of the immediate multidisciplinary approach to manage AEs.
CI  - (c) 2019 S. Karger AG, Basel.
FAU - Denaro, Nerina
AU  - Denaro N
AD  - Clinical Oncology and Translational Research, S. Croce e Carle University 
      Teaching Hospital, Cuneo, Italy, nerinadenaro@hotmail.com.
FAU - Latina, Adele
AU  - Latina A
AD  - Department of Endocrinology, Diabetes and Metabolism, S. Croce e Carle University 
      Teaching Hospital, Cuneo, Italy.
FAU - Cesario, Flora
AU  - Cesario F
AD  - Department of Endocrinology, Diabetes and Metabolism, S. Croce e Carle University 
      Teaching Hospital, Cuneo, Italy.
FAU - Bramardi, Fabio
AU  - Bramardi F
AD  - Department of Otolaryngology, S. Croce e Carle University Teaching Hospital, 
      Cuneo, Italy.
FAU - Corrado, Lauro
AU  - Corrado L
AD  - Department of General Surgery, S. Croce e Carle University Teaching Hospital, 
      Cuneo, Italy.
FAU - Borretta, Giorgio
AU  - Borretta G
AD  - Department of Endocrinology, Diabetes and Metabolism, S. Croce e Carle University 
      Teaching Hospital, Cuneo, Italy.
FAU - Merlano, Marco Carlo
AU  - Merlano MC
AD  - Clinical Oncology and Translational Research, S. Croce e Carle University 
      Teaching Hospital, Cuneo, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190807
PL  - Switzerland
TA  - Oncology
JT  - Oncology
JID - 0135054
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Iodine Radioisotopes)
RN  - 0 (Phenylurea Compounds)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Quinolines)
RN  - 9HW64Q8G6G (Everolimus)
RN  - EE083865G2 (lenvatinib)
SB  - IM
CIN - Oncology. 2019;97(4):189-190. PMID: 31390640
MH  - Antineoplastic Agents/therapeutic use
MH  - Carcinoma, Hepatocellular/drug therapy/radiotherapy
MH  - Carcinoma, Renal Cell/drug therapy/radiotherapy
MH  - Combined Modality Therapy/methods
MH  - Disease Progression
MH  - Disease-Free Survival
MH  - Everolimus/therapeutic use
MH  - Female
MH  - Humans
MH  - Iodine Radioisotopes/pharmacology
MH  - Liver Neoplasms/drug therapy/radiotherapy
MH  - Male
MH  - Phenylurea Compounds/*therapeutic use
MH  - Protein Kinase Inhibitors/therapeutic use
MH  - Quinolines/*therapeutic use
MH  - Thyroid Neoplasms/*drug therapy/radiotherapy
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Lenvatinib
OT  - Multidisciplinary approach
OT  - Thyroid cancer
OT  - Toxicity management
EDAT- 2019/08/08 06:00
MHDA- 2019/10/08 06:00
CRDT- 2019/08/08 06:00
PHST- 2019/05/17 00:00 [received]
PHST- 2019/05/29 00:00 [accepted]
PHST- 2019/08/08 06:00 [pubmed]
PHST- 2019/10/08 06:00 [medline]
PHST- 2019/08/08 06:00 [entrez]
AID - 000501691 [pii]
AID - 10.1159/000501691 [doi]
PST - ppublish
SO  - Oncology. 2019;97(4):206-210. doi: 10.1159/000501691. Epub 2019 Aug 7.